Scale, innovation leadership and transformation in focus at Elekta’s Capital Markets Day

STOCKHOLM, June 9, 2016 – At a Capital Markets Day in Stockholm, Elekta
presented how it will scale its businesses and capitalize on innovation
leadership. The ongoing transformation of the Company continues to be on track,
senior leaders said.
Elekta’s new President and CEO from June 10, Richard Hausmann, introduced
himself and said that he was “very much looking forward to leading this
innovative company through the transformation and beyond.” He expressed his
strong belief in the MR-linac project, which he called “impressive and very well
engineered.”

Tomas Puusepp, President and CEO until June 9, stated how the first year of
Elekta’s transformation program has strengthened the company’s competitiveness:
“We are quickly becoming a leaner company with an improved financial performance
and a clear focus on high growth areas: service, software and image guided
radiation therapy.”

Ian Alexander, Chief Commercial Officer (CCO), spoke of the potential made
possible by scaling Elekta’s service business: offering stable recurring
revenues at limited capital investment and improved profitability. “Service
continues to offer good growth potential in many markets, including mature
markets. In emerging markets, the service share of total revenues is about 15
percent. Our ambition is to grasp these opportunities as part of Elekta’s
transformational process.”

Håkan Bergström, Chief Financial Officer, stated that the transformation process
is on track. He reconfirmed the target to reach an EBITA margin of 20 percent by
fiscal year 2017/18. Cost reductions of SEK 700* million, with full effect in
fiscal year 2017/18, are expected to be met as planned. Net working capital to
sales ratio is already below the five percent target. For the first half of
fiscal year 2016/17, the company expects a one-off negative revenue effect of
SEK 500 million due to the change to producing to order, and therefore a weak
result for the first half of the year.

Elekta’s recently appointed Chief Technology Officer, John Lapré, focused on
capitalizing on the company’s innovation leadership, while setting the strategic
portfolio priorities and driving customer satisfaction. “Already today, Elekta
offers the most precise solutions in our industry, which is essential to
achieving good patient outcome when treating cancer. With MR-linac, the
precision will be significantly enhanced, enabling the start of a new era of
treating cancer. This research project, developed with a consortium and other
partners, is on track for commercial launch in 2017.”

Doctor Stella Mook, Radiation Oncologist at University Medical Center Utrecht
(UMC Utrecht), the Netherlands, is involved in research regarding MR-linac. She
demonstrated how esophageal cancer treatment could totally change with MR-linac.
She said that more than 100 professors, doctors, physicists and students at UMC
Utrecht are involved in research related to MR-linac.

*With fiscal year 2015/16 as base, excluding currency effects.

# # #

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 13:30 CET on June 9, 2016.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.